IP Library Granted Patent US 7,649,080
Granted Patent B2
US 7,649,080 · App. 11/895,553 · Granted Jan 19, 2010

Cross-linked glycopeptide-cephalosporin antibiotics

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,649,080
App. No.
11/895,553
Granted
Jan 19, 2010
Kind
B2
Abstract

This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.

Claims (28)

1. A process for preparing a compound of the formula:

or a salt thereof; the process comprising:

(a) contacting vancomycin or a salt thereof with a coupling reagent; and

(b) contacting the reaction mixture from step (a) with a compound of the formula:

or a salt thereof.

2. The process of claim 1 , wherein the coupling reagent comprises benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate and 1-hydroxybenzotriazole.

3. The process of claim 1 , wherein the coupling reagent comprises benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate and 1-hydroxy-7-azabenzotriazole.

4. The process of claim 1 , wherein the coupling reagent comprises O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate.

5. The process of claim 1 , wherein the process is conducted in a diluent comprising N,N-dimethylformamide, dimethyl sulfoxide, or a combination thereof.

6. The process of claim 1 , wherein step (a) of the process is conducted in the presence of diisopropylethylamine.

7. The process of claim 1 , wherein step (b) of the process is conducted in the presence of 2,4,6-collidine.

8. The process of claim 1 , wherein a vancomycin hydrochloride salt is employed in step (a).

9. A process for preparing a compound of the formula:

or a salt thereof; the process comprising reacting a compound of the formula:

or a salt thereof, with a reaction mixture formed by contacting vancomycin or a salt thereof with a coupling reagent.

10. The process of claim 9 , wherein the coupling reagent comprises benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate and 1-hydroxybenzotriazole.

11. The process of claim 9 , wherein the coupling reagent comprises benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate and 1-hydroxy-7-azabenzotriazole.

12. The process of claim 9 , wherein the coupling reagent comprises O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate.

13. The process of claim 9 , wherein the process is conducted in a diluent comprising N,N-dimethylformamide, dimethyl sulfoxide, or a combination thereof.

14. The process of claim 9 , wherein the process is conducted in the presence of 2,4,6-collidine.

15. A process for preparing a compound of the formula:

or a salt thereof; the process comprising:

(a) contacting vancomycin hydrochloride with a coupling reagent in the presence of diisopropylethylamine; and

(b) contacting the reaction mixture from step (a) with a compound of the formula:

or a salt thereof, in the presence of 2,4,6-collidine.

16. The process of claim 15 , wherein the coupling reagent comprises benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate and 1-hydroxybenzotriazole.

17. The process of claim 15 , wherein the coupling reagent comprises benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate and 1-hydroxy-7-azabenzotriazole.

18. The process of claim 15 , wherein the coupling reagent comprises O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2014
From: THERAVANCE, INC.
To: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
Reel/Frame 033179/0484 →